The IMW meeting 2017 in India has been outstanding and it’s still ongoing and very, very fascinating results. Something that I appreciated particularly is the coming back of the immune therapy. For many years we talked about vaccines in myeloma and it didn’t work and we talked also of monoclonal antibodies; we tried, at least in France and other countries, anti-IL6, anti-CD20 and nothing worked. But now we see a complete change in treatment paradigm and it starts with real effective efficacious monoclonal antibodies. The first one was elotuzumab but daratumumab, of course, and we even have new antibodies. This is the first very active for the first time monoclonal antibody but we heard today also a monoclonal antibody conjugated with drugs, so-called antibody drug conjugations, ADC, and these are promising. We have the so-called BiTEs, so antibodies with bispecific linkers, it looks very promising. We have T-cell therapy like CAR T-cells and on top of that we have the so-called checkpoint inhibitors and you can combine all of these and it will dramatically change the way we treat myeloma and it will, for sure, improve even more the survival of patients.